Skip to main
CRMD
CRMD logo

CorMedix (CRMD) Stock Forecast & Price Target

CorMedix (CRMD) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 55%
Buy 36%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Cormedix Inc. demonstrates a positive outlook due to its focused commercialization efforts of DefenCath, an FDA-approved solution aimed at preventing catheter-related bloodstream infections, which is gaining traction in both commercial and federal healthcare markets. The recent partnership with WSI PBG is expected to enhance DefenCath’s accessibility within the federal healthcare network, particularly benefiting a significant patient population, including veterans. Additionally, the company is investing in manufacturing scale-up and market education, reinforcing its commitment to establishing DefenCath as a new standard of care, thereby positioning itself for sustained revenue growth.

Bears say

Cormedix Inc faces a challenging market environment due to the significant burden of catheter-related bloodstream infections (CRBSIs), which contribute to increased healthcare costs and patient morbidity. The company's reliance on the commercialization of a single product, DefenCath, in the U.S. exposes it to risks associated with market acceptance and competitive pressures within a concentrated geographic focus. Furthermore, operating within a single segment limits diversification, which may hinder financial stability and growth potential in the face of industry challenges.

CorMedix (CRMD) has been analyzed by 11 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 36% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CorMedix (CRMD) Forecast

Analysts have given CorMedix (CRMD) a Buy based on their latest research and market trends.

According to 11 analysts, CorMedix (CRMD) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.05, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.05, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CorMedix (CRMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.